介入性心脏病学杂志》/2021年/文章/标签1

评论文章

双重抗血小板治疗的临床疗效和安全性在接受冠状动脉支架植入术的患者:系统回顾和荟萃分析网络

表1

汇集估计网络的荟萃分析缺血性和出血性的端点。

主要出血
榫眼12莫 0.67 (0.26,1.23) 0.67 (0.31,1.31) 0.58 (0.32,1.07) 0.77 (0.46,1.23) 1.50 (0.95,2.54)
1.49 (0.81,3.92) 榫眼1 mo + P2Y12 1.01 (0.39,3.15) 0.86 (0.37,2.81) 1.14 (0.52,3.39) 2.22 (1.07,7.12)
1.49 (0.76,3.27) 0.99 (0.32,2.59) 榫眼3莫+亚撒 0.85 (0.36,2.37) 1.15 (0.50,2.86) 2.26 (1.02,5.82)
1.74 (0.94,3.11) 1.16 (0.36,2.68) 1.18 (0.42,2.77) 榫眼3莫+ P2Y12 1.33 (0.60,2.75) 2.62 (1.21,5.63)
1.31 (0.81,2.17) 0.87 (0.29,1.91) 0.87 (0.35,2.01) 0.75 (0.36,1.67) 榫眼6个月 1.98 (1.21,3.50)
0.67 (0.39,1.05) 0.45 (0.14,0.93) 0.44 (0.17,0.98) 0.38 (0.18,0.82) 0.50 (0.29,0.83) L-DAPT

任何出血
榫眼12莫 0.74 (0.38,1.18) 0.74 (0.43,1.22) 0.58 (0.38,0.88) 0.76 (0.52,1.04) 1.48 (1.02,2.03)
1.35 (0.85,2.65) 榫眼1 mo + P2Y12 1.00 (0.51,2.29) 0.77 (0.43,1.77) 1.02 (0.58,2.11) 1.99 (1.13,4.14)
1.35 (0.82,2.30) 1.00 (0.44,1.95) 榫眼3莫+亚撒 0.79 (0.41,1.54) 1.03 (0.56,1.88) 2.01 (1.07,3.67)
1.73 (1.14,2.63) 1.29 (0.57,2.32) 1.27 (0.65,2.44) 榫眼3莫+ P2Y12 1.31 (0.75,2.20) 2.56 (1.46,4.29)
1.32 (0.96,1.91) 0.98 (0.47,1.71) 0.97 (0.53,1.80) 0.76 (0.45,1.34) 榫眼6个月 1.95 (1.37,2.74)
0.68 (0.49,0.98) 0.50 (0.24,0.89) 0.50 (0.27,0.94) 0.39 (0.23,0.68) 0.51 (0.37,0.73) L-DAPT

明确的或可能的支架血栓形成
榫眼12莫 1.20 (0.54,3.65) 1.25 (0.54,2.95) 1.00 (0.44,2.46) 1.09 (0.62,2.08) 0.58 (0.34,1.11)
0.83 (0.27,1.85) 榫眼1 mo + P2Y12 1.03 (0.25,3.28) 0.82 (0.21,2.75) 0.89 (0.28,2.53) 0.47 (0.15,1.35)
0.80 (0.34,1.87) 0.97 (0.30,3.96) 榫眼3莫+亚撒 0.79 (0.25,2.80) 0.87 (0.32,2.55) 0.46 (0.18,1.38)
1.00 (0.41,2.29) 1.23 (0.36,4.73) 1.26 (0.36,4.05) 榫眼3莫+ P2Y12 1.10 (0.39,3.10) 0.58 (0.21,1.67)
0.92 (0.48,1.62) 1.12 (0.39,3.58) 1.15 (0.39,3.13) 0.91 (0.32,2.58) 榫眼6个月 0.53 (0.29,0.98)
1.73 (0.90,2.91) 2.11 (0.74,6.59) 2.16 (0.72,5.66) 1.72 (0.60,4.73) 1.88 (1.02,3.40) L-DAPT

心肌梗死
榫眼12莫 1.03 (0.66,1.70) 1.10 (0.69,1.75) 0.84 (0.52,1.27) 1.12 (0.82,1.57) 0.68 (0.51,0.95)
0.97 (0.59,1.51) 榫眼1 mo + P2Y12 1.07 (0.53,2.04) 0.82 (0.40,1.45) 1.08 (0.63,1.92) 0.66 (0.38,1.17)
0.91 (0.57,1.46) 0.93 (0.49,1.90) 榫眼3莫+亚撒 0.76 (0.39,1.41) 1.01 (0.59,1.84) 0.62 (0.36,1.12)
1.19 (0.79,1.93) 1.22 (0.69,2.51) 1.32 (0.71,2.56) 榫眼3莫+ P2Y12 1.33 (0.80,2.45) 0.81 (0.50,1.51)
0.89 (0.64,1.22) 0.93 (0.52,1.60) 0.99 (0.54,1.71) 0.75 (0.41,1.25) 榫眼6个月 0.61 (0.43,0.87)
1.47 (1.06,1.95) 1.52 (0.86,2.62) 1.62 (0.89,2.78) 1.24 (0.66,2.02) 1.63 (1.15,2.34) L-DAPT

结果上三角形的优势比为95%的置信区间之间的网络荟萃分析列定义干预和行定义干预。大胆的重要结果。L-DAPT指长期(> 12个月)榫眼,榫眼12密苏里州指的是12个月的榫眼,榫眼6 mo指的是6个月榫眼,榫眼3莫+ ASA指三个月榫眼紧随其后的是阿司匹林单一疗法,榫眼3莫+ P2Y12指三个月榫眼后跟P2Y12受体抑制剂单一疗法,和榫眼1 mo + P2Y12指月榫眼P2Y12受体抑制剂单一疗法。榫眼表明双重抗血小板治疗。

文章奖:2020年杰出的研究贡献,选择由我们的首席编辑。获奖的文章阅读